The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil

Robert B Diasio, Martin R. Johnson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

There is increasing evidence supporting the important role of genetics in determining the effect (response and toxicity) to cancer chemotherapy. This has included both pharmacogenetics, where the alteration of a gene coding for an important drug metabolizing enzyme results in increased toxicity (and occasionally altered efficacy), and pharmacogenomics, where knowledge of the expression of genes critical to the action of the cancer chemotherapy drug can be used to individualize therapy. This manuscript focuses on the widely used cancer chemotherapy drug 5-fluorouracil (5-FU) to illustrate the following concepts: (1) The effect of the pharmacogenetic syndrome known as dihydropyrimidine dehydrogenase (DPD) deficiency on 5-FU pharmacology; (2) the role of pharmacogenomics in individualizing 5-FU therapy, and (3) the potential value of pharmacogenomics in designing new drugs. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalPharmacology
Volume61
Issue number3
StatePublished - Sep 2000
Externally publishedYes

Fingerprint

Pharmacogenetics
Fluorouracil
Drug Therapy
Neoplasms
Antineoplastic Agents
Dihydropyrimidine Dehydrogenase Deficiency
Pharmaceutical Preparations
Pharmacology
Gene Expression
Enzymes
Therapeutics
Genes

Keywords

  • 5-Fluorouracil
  • Dihydropyrimidine dehydrogenase
  • Pharmacogenetics/pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology

Cite this

The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. / Diasio, Robert B; Johnson, Martin R.

In: Pharmacology, Vol. 61, No. 3, 09.2000, p. 199-203.

Research output: Contribution to journalArticle

@article{5c74732f799d4e0a9be14e6358a70465,
title = "The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil",
abstract = "There is increasing evidence supporting the important role of genetics in determining the effect (response and toxicity) to cancer chemotherapy. This has included both pharmacogenetics, where the alteration of a gene coding for an important drug metabolizing enzyme results in increased toxicity (and occasionally altered efficacy), and pharmacogenomics, where knowledge of the expression of genes critical to the action of the cancer chemotherapy drug can be used to individualize therapy. This manuscript focuses on the widely used cancer chemotherapy drug 5-fluorouracil (5-FU) to illustrate the following concepts: (1) The effect of the pharmacogenetic syndrome known as dihydropyrimidine dehydrogenase (DPD) deficiency on 5-FU pharmacology; (2) the role of pharmacogenomics in individualizing 5-FU therapy, and (3) the potential value of pharmacogenomics in designing new drugs. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "5-Fluorouracil, Dihydropyrimidine dehydrogenase, Pharmacogenetics/pharmacogenomics",
author = "Diasio, {Robert B} and Johnson, {Martin R.}",
year = "2000",
month = "9",
language = "English (US)",
volume = "61",
pages = "199--203",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil

AU - Diasio, Robert B

AU - Johnson, Martin R.

PY - 2000/9

Y1 - 2000/9

N2 - There is increasing evidence supporting the important role of genetics in determining the effect (response and toxicity) to cancer chemotherapy. This has included both pharmacogenetics, where the alteration of a gene coding for an important drug metabolizing enzyme results in increased toxicity (and occasionally altered efficacy), and pharmacogenomics, where knowledge of the expression of genes critical to the action of the cancer chemotherapy drug can be used to individualize therapy. This manuscript focuses on the widely used cancer chemotherapy drug 5-fluorouracil (5-FU) to illustrate the following concepts: (1) The effect of the pharmacogenetic syndrome known as dihydropyrimidine dehydrogenase (DPD) deficiency on 5-FU pharmacology; (2) the role of pharmacogenomics in individualizing 5-FU therapy, and (3) the potential value of pharmacogenomics in designing new drugs. Copyright (C) 2000 S. Karger AG, Basel.

AB - There is increasing evidence supporting the important role of genetics in determining the effect (response and toxicity) to cancer chemotherapy. This has included both pharmacogenetics, where the alteration of a gene coding for an important drug metabolizing enzyme results in increased toxicity (and occasionally altered efficacy), and pharmacogenomics, where knowledge of the expression of genes critical to the action of the cancer chemotherapy drug can be used to individualize therapy. This manuscript focuses on the widely used cancer chemotherapy drug 5-fluorouracil (5-FU) to illustrate the following concepts: (1) The effect of the pharmacogenetic syndrome known as dihydropyrimidine dehydrogenase (DPD) deficiency on 5-FU pharmacology; (2) the role of pharmacogenomics in individualizing 5-FU therapy, and (3) the potential value of pharmacogenomics in designing new drugs. Copyright (C) 2000 S. Karger AG, Basel.

KW - 5-Fluorouracil

KW - Dihydropyrimidine dehydrogenase

KW - Pharmacogenetics/pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=0033832450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033832450&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 199

EP - 203

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 3

ER -